
Galapagos and BridGene Biosciences enter collaboration for oncology drug discovery
Betsy Goodfellow | January 4, 2024 | News story | Research and Development | BridGene Biosciences, Galapagos, Oncology, drug discovery, oncology
Galapagos NV and BridGene Biosciences have announced that they have entered into a strategic collaboration and licensing agreement for the discovery of novel small molecule drug candidates within oncology.
Under the terms of the agreement, Galapagos will pay BridGene $27m, comprising both upfront and preclinical research milestone payments, as well as a potential $700m in clinical and commercial milestones, if the programmes are successful.
BridGene will also be entitled to single-digit tiered royalties on net sales of any products resulting from this collaboration.
Pierre Raboisson PhD, senior vice president and head of Small Molecules Discovery at Galapagos, commented: “Our small molecule oncology strategy is focused on developing best-in-class precision medicines that have the potential to transform the lives of cancer patients, and today’s announcement has the potential to accelerate that objective. We are very pleased to announce this preclinical research collaboration with BridGene, which has a strong track record in small molecule drug discovery for challenging targets. We look forward to working together and leveraging the unique capabilities of each company with the goal of developing transformative medicines to address high unmet medical needs of cancer patients.”
Betsy Goodfellow
Related Content

Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by …

Bio-Rad signs exclusive European distribution deal with Gencurix for oncology testing kits
The agreement expands access to oncology testing kits across Europe






